Armata Pharmaceuticals (ARMP) Receivables (2013 - 2023)

Armata Pharmaceuticals has disclosed Receivables across 9 years of filings, most recently posting $1.8 million for Q4 2023.

• Receivables for Q4 2023 came in at $1.8 million, down 78.9% year-over-year; the trailing twelve-month figure through Dec 2023 was $1.8 million (down 78.9% YoY), and the FY2023 annual result was $1.8 million, down 78.9% from the prior year.
• Receivables came in at $1.8 million for Q4 2023 at Armata Pharmaceuticals, up from $1.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $8.5 million in Q4 2022 to a low of $335000.0 in Q3 2020.
• The 4-year median for Receivables is $1.3 million (2021), against an average of $1.9 million.
• Across the five-year window, Receivables surged 432.8% in 2021 and sank 78.9% in 2023, its largest moves.
• Armata Pharmaceuticals' Receivables stood at $561000.0 in 2020, then soared by 432.8% to $3.0 million in 2021, then jumped by 185.41% to $8.5 million in 2022, then tumbled by 78.9% to $1.8 million in 2023.
• The last three Receivables figures came in at $1.8 million (Q4 2023), $1.3 million (Q1 2023), and $8.5 million (Q4 2022), per Business Quant data.